已收录 273192 条政策
 政策提纲
  • 暂无提纲
Palivizumab for the prevention of respiratory syncytial virus infection
[摘要] QUESTION Palivizumab, a specific monoclonal antibody for respiratory syncytial virus (RSV), is available for prevention of pediatric respiratory tract infections. What are the indications for its use and can it be used for treatment of RSV infections? ANSWER Most infants should not be considered for RSV prophylaxis with palivizumab. The drug is approved for use for different indications in different Canadian provinces. The drug should be administered only in the context of infants most vulnerable to severe RSV illness with a high likelihood of hospital admission, particularly in the first 6 months of life. It is not effective in the treatment of RSV disease and it is not approved or recommended for this indication.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 卫生学
[关键词] friction factors;wind measurements;tsunami [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文